Osteoarthritis, colloquially known as “wear-and-tear arthritis”, is the most common form of arthritis, frequently affecting the joints of the hands, feet, knees, hips and spine. It involves degeneration of articular cartilage, which exposes the underlying subchondral bone, resulting in sclerosis and subsequent bone remodelling which ultimately leads to a narrowing of the joint space.
Pain and loss of function are the hallmark symptoms of osteoarthritis. Swelling and stiffness of the affected joint is often apparent, with enlargement of the fingers around the interphalangeal joints particularly common where the hands are affected.
First-line treatment for osteoarthritis involves non-pharmacological methods, with a particular focus on education and encouraging weight loss among overweight patients. This may be supplemented with analgesics and NSAIDs as required. In some cases, intra-articular corticosteroid injections provide short term pain relief, and where conservative therapy proves ineffectual, surgery may also be considered.
To find out more about Osteoarthritis, visit our dedicated Learning Zone, which contains further information on the management of this condition.
Latest Clinical Guidelines, Trials and Journals
This study attempts to observe the effectiveness and safety of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to clarify the characteristics...
These updated guidelines on the management of variceal haemorrhage have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the liver section of the BSG.
Latest news and insights
Epizyme announced that the FDA has accepted for filing the company's New Drug Application (NDA) for the accelerated approval of Tazverik (tazemetostat) for patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy.
Bristol-Myers Squibb announced that the FDA has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel), the company's autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy
Biotronik has announced CE Mark certification for the Orsiro Mission drug-eluting stent (DES) system. The next generation of the company's ultrathin strut Orsiro DES provides higher deliverability than other contemporary stents. Orsiro Mission is now available in CE Mark countries.